Drew Moghanaki, Professor, Chief of Thoracic Oncology at the Department of Radiation Oncology and Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at David Geffen School of Medicine at UCLA, and Chief Medical Officer of Respirati, shared a post on X:
“A highly informative presentation by Scott Bratman at ASTRO25 describes which clinical settings ctDNA performs best and where it
may struggle to provide a meaningful clinical signal.
It was confirmed that he isn’t the only one who holds this opinion on the matter.
I was intrigued to learn about the sources of “noise” interfering with ctDNA test results.
Next up was Aadel Chaudhuri reiterating the limitations of ctDNA for the detection of precancerous and stage I tumors.
For those who want to think about this more, it was recommended to pull this article by Siddhartha Mukherjee.”
More posts featuring Drew Moghanaki on OncoDaily.